OncoMatch/Clinical Trials/NCT06586255
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Is NCT06586255 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for urothelial carcinoma bladder.
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage T3 OR HIGHER, ANY N (AJCC, 7th Ed.)
Pathologic T3 or higher stage disease, any N, M0 (AJCC, 7th Ed., Appendix C)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radical cystectomy and pelvic lymph node dissection
Radical cystectomy and pelvic lymph node dissection within the prior 48 weeks
Must have received: checkpoint inhibitor — adjuvant
Receiving adjuvant checkpoint inhibitor therapy
Cannot have received: radiation therapy
Exception: Prior radiation therapy for a different cancer or disease process is allowed, provided there will be no overlap of radiation therapy fields between the participant's prior and current course of radiation therapy, radiotherapy was completed more than four weeks from enrolling in this study.
No prior radiotherapy to the region of study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify